Summary
CVS/Caremark Corporation reported significant growth in its first quarter of 2007, with net revenues reaching $13.18 billion, a substantial increase from $9.98 billion in the same period of the prior year. This growth was largely driven by the acquisition of Caremark Rx, Inc. which closed on March 22, 2007, effectively combining a leading retail pharmacy chain with a major pharmacy benefit manager (PBM). The combined entity reported strong performance across both its Retail Pharmacy and PBM segments, with the PBM segment showing particularly impressive revenue growth due to the merger. Despite the positive revenue trend, the company's gross profit margin slightly decreased from 26.6% to 25.4% year-over-year. This was attributed to factors such as increased generic drug utilization impacting reimbursement rates, a growing proportion of third-party pharmacy revenues which generally have lower margins, and the migration of profitable business to Medicare Part D plans. The company also incurred merger-related integration costs. However, net earnings available to common shareholders increased to $405.4 million from $326.1 million in the prior year, demonstrating the overall positive impact of the Caremark merger on profitability, even with the noted cost pressures and margin compression. Financially, the company saw a significant increase in net cash provided by operating activities, jumping from $171.7 million to $707.7 million, largely due to increased cash receipts from revenues post-merger. Investing activities showed a substantial outflow of $2.3 billion, primarily reflecting the merger-related expenditures. Financing activities provided $1.7 billion in cash, primarily from increased short-term borrowings to fund the merger. The company also announced a 23% increase in its quarterly common stock dividend.
Key Highlights
- 1Net revenues surged by 32.1% to $13.18 billion for the thirteen weeks ended March 31, 2007, compared to $9.98 billion in the prior year, primarily due to the completion of the Caremark merger.
- 2The acquisition of Caremark Rx, Inc. on March 22, 2007, significantly expanded the company's PBM segment, leading to a 136.8% increase in PBM net revenue.
- 3Net earnings available to common shareholders increased by 24.1% to $405.4 million ($0.45 per basic share, $0.43 per diluted share) from $326.1 million ($0.40 per basic share, $0.39 per diluted share) in the prior year.
- 4Gross profit margin decreased slightly from 26.6% to 25.4%, influenced by factors such as increased generic drug utilization, a higher mix of third-party payor revenues, and Medicare Part D program dynamics.
- 5Net cash provided by operating activities increased significantly to $707.7 million from $171.7 million, reflecting improved cash generation post-merger.
- 6The company announced a 23% increase in its quarterly common stock dividend to $0.06 per share.
- 7Goodwill increased substantially to $28.5 billion as of March 31, 2007, up from $3.2 billion at year-end 2006, primarily due to the Caremark merger accounting for $25.3 billion in goodwill.